EANS-Adhoc: Intercell AG / Intercell announces new management structure: Thomas Lingelbach appointed new CEO; new Supervisory Board members proposed

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

Company Information

05.05.2011

Vienna (Austria), May 5, 2011 - Today Intercell AG (VSE: ICLL)
announced that the company´s Supervisory Board has appointed Thomas
Lingelbach as new Chief Executive Officer (CEO) for Intercell,
effective May 10, 2011.

At the same time, Gerd Zettlmeissl, current CEO, will resign to
pursue other personal and professional interests. Under his
excellent leadership, Intercell received international approval for
the novel Japanese Encephalitis vaccine, IXIARO®/JESPECT®, formed
major strategic alliances with leading pharmaceutical companies and
vaccine non-profit organizations, successfully completed several
financing steps, was elected as `Technology Pioneer´ at the World
Economic Forum in 2009 and received the European Biotechnica Award in
2006.

The company will propose to the next General Assembly the election of
two new members of the Supervisory Board, Alexander von Gabain, and
Thomas Szucs, both of whom have extended experience in the field of
vaccines and pharmaceutical development. One current member of the
Supervisory Board, David Ebsworth, intends to resign due to the
demands on his time required by recent increased executive
responsibilities he is taking on in Switzerland as CEO of Galenica
AG.

Michel Gréco, Chairperson of the Supervisory Board comments that "The
Supervisory Board appreciates very much that Thomas Lingelbach will
take over the CEO position. His impressive experience in the
industry and at Intercell uniquely qualifies him for his new role to
adapt the strategy for the company´s future. We want to express our
sincere thanks to Gerd Zettlmeissl for his leadership, vision and
many years of hard work to grow Intercell into a leader in vaccine
biotechnology and wish him all the best for his future. I also
welcome the possibility of working with the proposed incoming very
experienced Supervisory Board colleagues, and I would like to thank
David Ebsworth for his productive contributions during his years on
the Board."

Thomas Lingelbach has more than twenty years of experience in the
pharma and vaccines industry, having held a variety of leading
positions of increasing international responsibility at Hoechst AG,
Chiron Vaccines, and Novartis Vaccines and Diagnostics, before
joining Intercell in 2006 as Chief Operating Officer. His experience
ranges broadly and deeply in the areas of Industrial Operations,
Product Development, and Commercial Operations. At Intercell, Thomas
Lingelbach has been inter alia chiefly responsible for the
manufacturing and March 2009 licensure in the U.S. and Europe of the
company´s first product, a vaccine to prevent Japanese Encephalitis.

Thomas Lingelbach stated: "I will be delighted to work as the new CEO with the
experienced Management Board of Intercell, Staph Bakali, who joined the
Management Board last year as Chief Business Officer, and Reinhard Kandera,
Chief Financial Officer. Together with our talented senior executives we will
strive to maximize the value of the company based on its strong foundation of
human and technological capital. Intercell is in the heart of a rapidly
changing field of the biotech and pharmaceutical business, and I welcome the
responsibility for adapting Intercell to its future challenges."
Gerd Zettlmeissl commented: "After an excellent experience with Intercell over
ten years, I am happy to hand over the leadership of Intercell to a highly
experienced Management Board team led by Thomas Lingelbach which ideally
combines all capabilities to lead Intercell into its next stage of development."

By proposing two new members, Alexander von Gabain and Thomas Szucs, for
election by the shareholders to the Supervisory Board, the company intends to
diversify the Board´s pharmaceutical competence.
Alexander von Gabain is already known to many of Intercell´s shareholders as one
of the company´s founders and as a former Intercell CEO who brought the company
public. As former Chief Scientific Officer he leveraged Intercell´s technology
platforms and scientific reputation. In his academic career, Alexander von
Gabain has also served as Chairman of the Department of Microbiology and
Genetics at the University of Vienna and as Professor at the Karolinska
Institute, Stockholm, Sweden, and at both organizations, he is still an
appointed Professor. Recently, it was announced that he will be the next
Chairperson of the Board of the European Institute of Innovation and Technology
(EIT).

Thomas Szucs is an MD, MBA, MPH, and LLM, board certified in Preventive Medicine
as well as Pharmaceutical Medicine, and has held various positions in industry,
hospital management, and consulting before joining academia. He is Professor
and Director of the European Center of Pharmaceutical Medicine of the University
of Basel. In addition, he is Chairman of BB Biotech, and Chairman of the
largest Swiss health insurer, Helsana AG. His principal interest is healthcare
policy and economics as well as drugs/vaccines development.

More complete information about each of these proposed candidates for membership
on Intercell´s Supervisory Board will be available prior to the annual
shareholders´ meeting.

The announcement about the change of the CEO is occurring in advance
of the planned handover to maintain the company´s commitment to
timely disclosure of information in compliance with relevant Austrian
requirements and as a means of facilitating a smooth transition of
responsibilities. In this context, Gerd Zettlmeissl and Thomas
Lingelbach will co-chair the company´s next quarterly call on May 10.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market